Greater China News
UK drug giant AstraZeneca to set up research base in Hong Kong, city’s finance chief Paul Chan reveals on Europe work trip
Leading global pharmaceutical firm AstraZeneca will set up a research and development centre in Hong Kong, the city’s finance minister has revealed while on a work trip in Europe.
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
The ADSs are expected to begin trading on the Nasdaq Global Market on September 29, 2023 under the ticker symbol “ANL”.
Wuhan YZY Biopharma – HK$176 Million IPO
Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share.
United States and China launch economic and financial working groups with aim of easing tensions
The U.S. Treasury Department and China’s Ministry of Finance launched a pair of economic working groups on Friday in an effort to ease tensions and deepen ties between the nations.
Pharming shortlisted for prestigious Scrip awards 2023
Pharming shortlisted in two categories, including “Biotech Company of the Year” and “Best New Drug”
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
The combined funds from this financing round and the company's reserves will provide ample capital to support the rapid product iteration and global development of gene-edited stem cell products by Qihan in the next four years.
Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC Venture Capital
On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding 300 million yuan.
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
Following Series C1 financing on May 31, this new funding marks another step in the company's continuous growth, bringing the total amount raised in the C-round to 322 million RMB. HaoYue Capital acted as the exclusive financial advisor in this transaction.
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA, which is estimated to be on or around 2026.
